Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 469

1.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 May 9. pii: S0140-6736(19)30723-8. doi: 10.1016/S0140-6736(19)30723-8. [Epub ahead of print]

PMID:
31079938
2.

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B.

Clin Genitourin Cancer. 2019 Apr 1. pii: S1558-7673(19)30109-0. doi: 10.1016/j.clgc.2019.03.017. [Epub ahead of print]

PMID:
31072748
3.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee.

Ann Oncol. 2019 Feb 21. pii: mdz056. doi: 10.1093/annonc/mdz056. [Epub ahead of print] No abstract available.

PMID:
30788497
4.

Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

Escudier B.

N Engl J Med. 2019 Mar 21;380(12):1176-1178. doi: 10.1056/NEJMe1900887. Epub 2019 Feb 16. No abstract available.

PMID:
30779526
5.

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.

Derosa L, Bayar MA, Albiges L, Le Teuff G, Escudier B.

Angiogenesis. 2019 Feb 9. doi: 10.1007/s10456-019-09664-2. [Epub ahead of print]

PMID:
30739258
6.

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.

Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ.

Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15.

PMID:
30658932
7.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5.

PMID:
30616146
8.

Sorafenib: key lessons from over 10 years of experience.

Escudier B, Worden F, Kudo M.

Expert Rev Anticancer Ther. 2018 Dec 21:1-13. doi: 10.1080/14737140.2019.1559058. [Epub ahead of print]

PMID:
30575405
9.

Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.

Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G, Loriot Y, Fizazi K, Albiges L.

Eur J Cancer. 2019 Jan;107:79-85. doi: 10.1016/j.ejca.2018.10.023. Epub 2018 Dec 11.

PMID:
30551078
10.

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

Rochigneux P, Thomassin-Piana J, Laibe S, Brunelle S, Salem N, Escudier B, Vassal G, Gravis G.

BMC Cancer. 2018 Nov 22;18(1):1159. doi: 10.1186/s12885-018-5049-3. Review.

11.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

12.

Sunitinib Alone or after Nephrectomy in Renal Cancer.

Escudier B, Thezenas S, Méjean A.

N Engl J Med. 2018 Nov 8;379(19):1878. doi: 10.1056/NEJMc1811532. No abstract available.

PMID:
30403947
13.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

PMID:
30401688
14.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
15.

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.

Lebacle C, Bensalah K, Bernhard JC, Albiges L, Laguerre B, Gross-Goupil M, Baumert H, Lang H, Tricard T, Duclos B, Arnoux A, Piedvache C, Patard JJ, Escudier B.

BJU Int. 2019 May;123(5):804-810. doi: 10.1111/bju.14581. Epub 2018 Nov 20.

PMID:
30288884
16.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
17.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

PMID:
30197417
18.

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Flippot R, Escudier B, Albiges L.

Drugs. 2018 Sep;78(14):1443-1457. doi: 10.1007/s40265-018-0970-y. Review.

PMID:
30187355
19.

Treating patients with renal cell carcinoma and bone metastases.

Guida A, Escudier B, Albiges L.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1135-1143. doi: 10.1080/14737140.2018.1520097. Epub 2018 Sep 13. Review.

PMID:
30183421
20.

The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.

Calvo E, Porta C, Grünwald V, Escudier B.

Oncologist. 2019 Mar;24(3):338-348. doi: 10.1634/theoncologist.2018-0267. Epub 2018 Aug 29. Review.

PMID:
30158285
21.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic.

Patrikidou A, Maroun P, Patard JJ, Baumert H, Albiges L, Massard C, Loriot Y, Escudier B, Di Palma M, Arfi-Rouche J, Rocher L, Merabet Z, Bossi A, Fizazi K, Blanchard P.

Clin Transl Radiat Oncol. 2018 Jul 6;12:28-33. doi: 10.1016/j.ctro.2018.07.001. eCollection 2018 Aug.

22.

The role of tivozanib in advanced renal cell carcinoma therapy.

Escudier B, Porta C, Eisen T, Belsey J, Gibson D, Morgan J, Motzer R.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1113-1124. doi: 10.1080/14737140.2018.1508348. Epub 2018 Aug 21. Review.

PMID:
30084668
23.

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies.

Denouel A, Heutte N, Escudier B, Kurtz JE, Dos Santos M, Longato N, Desrues L, Dauchy S, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Noal S, Joly F.

Clin Genitourin Cancer. 2018 Oct;16(5):369-375.e1. doi: 10.1016/j.clgc.2018.05.013. Epub 2018 May 21.

PMID:
30007862
24.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29867230
25.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

26.

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A.

Eur Urol. 2018 Nov;74(5):611-620. doi: 10.1016/j.eururo.2018.05.002. Epub 2018 May 18. Review.

PMID:
29784193
27.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
28.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

PMID:
29617710
29.

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.

Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK.

Br J Cancer. 2018 May;118(9):1176-1178. doi: 10.1038/s41416-018-0061-6. Epub 2018 Mar 26.

30.

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I.

Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

31.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

32.

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors.

Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B.

Clin Genitourin Cancer. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014. Epub 2018 Jan 4.

PMID:
29428404
33.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.

PMID:
29377755
34.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

35.

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8.

PMID:
29309249
36.

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 3. No abstract available.

PMID:
29306512
37.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761
39.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
40.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

PMID:
28967554
41.

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

Escudier B, Staehler M.

Eur Urol. 2018 Jan;73(1):1-3. doi: 10.1016/j.eururo.2017.08.020. Epub 2017 Sep 8.

PMID:
28890247
42.

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Guida A, Albiges L, Derosa L, Loriot Y, Massard C, Fizazi K, Escudier B.

Clin Genitourin Cancer. 2017 Dec;15(6):e1081-e1088. doi: 10.1016/j.clgc.2017.07.015. Epub 2017 Aug 12.

PMID:
28888866
43.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G.

Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

44.

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.

Négrier S, Pérol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B.

BMC Cancer. 2017 Aug 15;17(1):547. doi: 10.1186/s12885-017-3527-7.

45.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.

Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget JC, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A.

Target Oncol. 2017 Oct;12(5):655-661. doi: 10.1007/s11523-017-0525-2.

PMID:
28798986
46.

Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer.

Joly F, Heutte N, Duclos B, Noal S, Léger-Hardy I, Dauchy S, Longato N, Desrues L, Houede N, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Escudier B.

Eur Urol Focus. 2016 Dec 15;2(6):642-649. doi: 10.1016/j.euf.2016.04.009. Epub 2016 May 17.

PMID:
28723499
47.

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G.

Eur Urol Focus. 2016 Dec 15;2(6):582-588. doi: 10.1016/j.euf.2017.04.002. Epub 2017 Apr 20. Review.

PMID:
28723489
48.

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B.

Clin Genitourin Cancer. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005. [Epub ahead of print]

PMID:
28711490
49.

Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.

Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D, Deliveliotis C, Dimopoulos MA, Constantinides CA.

Oncologist. 2017 Jun;22(6):667-679. doi: 10.1634/theoncologist.2016-0435. Epub 2017 Jun 7. Review.

50.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248

Supplemental Content

Loading ...
Support Center